Antitumor effects of a novel Chromosome Region Maintenance 1 (CRM1) inhibitor on non-small cell lung cancer cells in vitro and in mouse tumor xenografts

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Wang, Shuai ^a   Han, Xiaohong ^a   Wang, Jianfei ^a   Yao, Jiarui ^a   Shi, Yuankai ^a  

^a CANCER HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CASPASE 3; CASPASE 8; CASPASE 9; CHROMOSOME REGION MAINTENANCE 1 INHIBITOR; EXPORTIN 1; GEFITINIB; KPT 185; KPT 276; SURVIVIN; UNCLASSIFIED DRUG; ACRYLIC ACID DERIVATIVE; CASPASE; CELL RECEPTOR; EXPORTIN 1 PROTEIN; KARYOPHERIN; KPT-185; TRIAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER RESISTANCE; CELL STRAIN; CELL STRAIN H1650GR; CELL STRAIN H1975; CELL TRANSFORMATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVATION; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MOUSE; NOD SCID MOUSE; NONHUMAN; PROTEIN EXPRESSION; TUMOR XENOGRAFT; WEIGHT REDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE CHECKPOINT; CELL PROLIFERATION; CELL SURVIVAL; DOWN REGULATION; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; LUNG NEOPLASMS; METABOLISM; NONOBESE DIABETIC MOUSE; PATHOLOGY; SCID MOUSE; TUMOR CELL LINE;

ACRYLATES; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CASPASES; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOWN-REGULATION; ENZYME ACTIVATION; HUMANS; KARYOPHERINS; LUNG NEOPLASMS; MICE, INBRED NOD; MICE, SCID; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRIAZOLES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84897059570     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0089848     Document Type: Article

References (33)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Ramalingam SS, Owonikoko TK, Khuri FR (2011) Lung cancer: New biological insights and recent therapeutic advances. CA Cancer J Clin 61: 91-112.
3. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, et al. (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947-957.
4. Turner JG, Dawson J, Sullivan DM (2012) Nuclear export of proteins and drug resistance in cancer. Biochem Pharmacol 83: 1021-1032.
5. Fornerod M, Ohno M, Yoshida M, Mattaj IW (1997) CRM1 is an export receptor for leucine-rich nuclear export signals. Cell 90: 1051-1060. (Pubitemid 27408519)
6. Fukuda M, Asano S, Nakamura T, Adachi M, Yoshida M (1997) CRM1 is responsible for intracellular transport meditted by the nuclear export signal. Nature 390: 308-311. (Pubitemid 27513316)
7. Xu D, Farmer A, Chook YM (2010) Recognition of nuclear targeting signals by Karyopherin-beta proteins. Curr Opin Struct Biol 20: 782-790.
8. Murakami N, Ye Y, Kawanishi M, Aoki S, Kudo N, et al. (2002) New Rev-transport inhibitor with anti-HIV activity from Valerianae Radix. Bioorg Med Chem Lett 12: 2807-2810. (Pubitemid 35266738)
9. Stommel JM, Marchenko ND, Jimenez GS, Moll UM, Hope TJ, et al. (1999) A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular ocalization and p53 activity by NES masking. EMBO J.;18:1660-1672. (Pubitemid 29127078)
10. Bartholomeusz G, Wu Y, Ali Seyed M, Xia W, Kwong KY, et al. (2006) Nuclear translocation of the pro-apoptotic Bcl-2 family member Bok induces apoptosis. Mol Carcinog 45:73-83. (Pubitemid 43204507)
11. Meissner T, Krause E, Vinkemeier U (2004) Ratjadone and leptomycin B block CRM1- dependent nuclear export by identical mechanisms. FEBS Lett 576: 27-30. (Pubitemid 39330451)
12. Mutka SC, Yang WQ, Dong SD, Ward SL, Craig DA, et al. (2009) Identification of nuclear export inhibitors with potent anticancer activity in vivo. Cancer Res 69: 510-517.
13. Sakakibara K, Saito N, Sato T, Suzuki A, Hasegawa Y, et al. (2011) CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity. Blood 118: 3922-3931.
14. Van Neck T, Pannecouque C, Vanstreels E, Stevens M, Dehaen W, et al. (2008) Inhibition of the CRM1-mediated nucleocytoplasmic transport by N-azolylacrylates: structure-activity relationship and mechanism of action. Bioorg Med Chem 16: 9487-9497.
15. Wach JY, Guttinger S, Kutay U, Gademann K (2010) The cytotoxic styryl lactone goniothalamin is an inhibitor of nucleocytoplasmic transport. Bioorg Med Chem Lett 20: 2843-2846.
16. Dong X, Biswas A, Suel KE, Jackson LK, Martinez R, et al. (2009) Structural basis for leucine-rich nuclear export signal recognition by CRM1. Nature 458: 1136-1141.
17. Monecke T, Guttler T, Neumann P, Dickmanns A, Görlich D, et al. (2009) Crystal structure of the nuclear export receptor CRM1 in complex with Snurportin1 and 487 RanGTP. Science 324: 1087-1091.
18. Newlands ES, Rustin GJ, Brampton MH (1996) Phase I trial of elactocin. Br J Cancer 74:648-649. (Pubitemid 26279064)
19. Mutka SC, Yang WQ, Dong SD, Ward SL, Craig DA, et al. (2009) Identification of nuclear export inhibitors with potent anticancer activity in vivo. Cancer Res 69:510-517.
20. Azmi AS, Aboukameel A, Bao B, Sarkar FH, Philip PA, et al. (2013) Selective inhibitors of nuclear export block pancreatic cancer cell proliferation and reduce tumor growth in mice. Gastroenterology 144:447-456.
21. Etchin J, Sun Q, Kentsis A, Farmer A, Zhang ZC, et al. (2013) Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells. Leukemia 27:66-74.
22. Zhang K, Wang M, Tamayo AT, Shacham S, Kauffman M, et al. (2013) Novel selective inhibitors of nuclear export CRM1 antagonists for therapy in mantle cell lymphoma. Exp Hematol 41:67-78.
23. Noske A, Weichert W, Niesporek S, Röske A, Buckendahl AC, et al. (2008) Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer. Cancer 112:1733-1743. (Pubitemid 351536833)
24. Bonazzi S, Eidam O, Güttinger S, Wach JY, Zemp I, et al. (2010) Anguinomycins and derivatives: total syntheses, modeling, and biological evaluation of the inhibition of nucleocytoplasmic transport. J Am Chem Soc 132:1432-1442.
25. Kau TR, Schroeder F, Ramaswamy S, Wojciechowski CL, Zhao JJ, et al. (2003) A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells. Cancer Cell 4:463-476. (Pubitemid 38050043)
26. Keller SA, Schattner EJ, Cesarman E (2000) Inhibition of NF-kappaB induces apoptosis of KSHV-infected primary effusion lymphoma cells. Blood 96:2537-2542.
27. Cahir-McFarland ED, Davidson DM, Schauer SL, Duong J, Kieff E (2000) NF-kappa B inhibition causes spontaneous apoptosis in Epstein-Barr virus-transformed lymphoblastoid cells. Proc Natl Acad Sci U S A 97:6055-6060. (Pubitemid 30367522)
28. Phelps RM, Johnson BE, Ihde DC, Gazdar AF, Carbone DP, et al. (1996) NCI-Navy Medical Oncology Branch cell line data base. J Cell Biochem Suppl 24:32-91.
29. Herbst RS, Heymach JV, Lippman SM (2008) Lung cancer. N Engl J Med 359:1367-1380.
30. Noske A, Schwabe M, Weichert W, Darb-Esfahani S, Buckendahl AC, et al. (2011) An intracellular targeted antibody detects EGFR as an independent prognostic factor in ovarian carcinomas. BMC Cancer 11:294.
31. Lo HW, Ali-Seyed M, Wu Y, Bartholomeusz G, Hsu SC, et al. (2006) Nuclearcytoplasmic transport of EGFR involves receptor endocytosis, importin beta1 and CRM1. J Cell Biochem 98:1570-1583. (Pubitemid 44141861)
32. Hengartner MO (2000) The biochemistry of apoptosis. Nature 407:770-776.
33. Mutka SC, Yang WQ, Dong SD, Ward SL, Craig DA, et al. (2009) Identification of nuclear export inhibitors with potent anticancer activity in vivo. Cancer Res 69:510-517.